Antistaphylococcal β-Lactams versus Vancomycin for Treatment of Infective Endocarditis Due to Methicillin-Susceptible Coagulase-Negative Staphylococci: a Prospective Cohort Study from the International Collaboration on Endocarditis

Carugati, Manuela; Petti, Cathy A.; Arnold, Christopher; Miró, José M.; Pericàs, Juan M.; Mària, C. García de la; Kanafani, Zeina A.; Durante‐Mangoni, Emanuele; Baddley, John W.; Wray, Dannah; Klein, John L.; Delahaye, François; Fernández-Hidalgo, Núria; Hannan, Margaret M.; Murdoch, David R.; Bayer, Arnold S.; Chu, Vivian H.

doi:10.1128/aac.01531-16

Cited by 7 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In allergic patients or in those with infections caused by strains resistant to beta-lactams, the alternative is usually another cell wall-active agent, such as vancomycin for the viridans group streptococci and E. faecalis or vancomycin or daptomycin for staphylococci. Due to the limited amount of evidence, treatment regimens for endocarditis caused by coagulase-negative staphylococci are usually extrapolated from those recommended for treating endocarditis caused by S. aureus ( 126 ).…”

Section: Managementmentioning

confidence: 99%

Current Challenges in the Management of Infective Endocarditis

et al. 2021

View full text Add to dashboard Cite

Infective endocarditis is a relatively rare, but deadly cause of sepsis, with an overall mortality ranging from 20 to 25% in most series. Although the classic clinical classification into syndromes of acute or subacute endocarditis have not completely lost their usefulness, current clinical forms have changed according to the profound epidemiological changes observed in developed countries. In this review, we aim to address the changing epidemiology of endocarditis, several recent advances in the understanding of the pathophysiology of endocarditis and endocarditis-triggered sepsis, new useful diagnostic tools as well as current concepts in the medical and surgical management of this disease. Given its complexity, the management of infective endocarditis requires the close collaboration of multidisciplinary endocarditis teams that must decide on the diagnostic approach; the appropriate initial treatment in the critical phase; the detection of patients needing surgery and the timing of this intervention; and finally the accurate selection of patients for out-of-hospital treatment, either at home hospitalization or with oral antibiotic treatment.

show abstract

Section: Managementmentioning

confidence: 99%

Current Challenges in the Management of Infective Endocarditis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For endocarditis caused by coagulase-negative staphylococci, often produced by methicillin-resistant strains, the recommended regimens for treating S. aureus are usually extrapolated. 73…”

Section: Antimicrobial Treatmentmentioning

confidence: 99%

Infective Endocarditis: New Challenges in a Classic Disease

Cuervo

Hernández‐Meneses

Falces

et al. 2022

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Infective endocarditis is a relatively rare, but deadly infection, with an overall mortality of around 20% in most series. Clinical manifestations have evolved in response to significant epidemiological shifts in industrialized nations, with a move toward a nosocomial or health-care-related pattern, in older patients, with more episodes associated with prostheses and/or intravascular electronic devices and a predominance of staphylococcal and enterococcal etiology.Diagnosis is often challenging and is based on the conjunction of clinical, microbiological, and imaging information, with notable progress in recent years in the accuracy of echocardiographic data, coupled with the recent emergence of other useful imaging techniques such as cardiac computed tomography (CT) and nuclear medicine tools, particularly 18F-fluorodeoxyglucose positron emission/CT.The choice of an appropriate treatment for each specific case is complex, both in terms of the selection of the appropriate agent and doses and durations of therapy as well as the possibility of using combined bactericidal antibiotic regimens in the initial phase and finalizing treatment at home in patients with good evolution with outpatient oral or parenteral antimicrobial therapies programs. A relevant proportion of patients will also require valve surgery during the active phase of treatment, the timing of which is extremely difficult to define. For all the above, the management of infective endocarditis requires a close collaboration of multidisciplinary endocarditis teams.

show abstract